36 results about "Sex Hormone Binding Protein" patented technology

The disclosed methods and compositions for reducing cardiovascular risk factors in mammals generally includes using genistein to modulate various inflammatory and cardiovascular risk markers including: homocysteine, C-reactive protein, fibrinogen, sex hormone-binding globulin, fasting glucose, insulin, insulin resistance, and osteoprotegerin.

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Sex Hormone Binding Globulin (SHBG), in particular, by targeting natural antisense polynucleotides of Sex Hormone Binding Globulin (SHBG). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of SHBG.

The present invention relates to a molecular marking method for pig litter size. The method comprises the steps of pig genome DNA extraction, exon 6 primer design of sex hormone binding globulin (SHBG) genes, amplification in vitro and genotype detection. The present invention first discovers pig SHBG genes, discovers the obvious relationship between the polymorphism of exon 6 and pig litter size, and develops a restriction fragment enzyme digestion polymorphism detection method for detecting exon 6 mutational sites. The method can be used for the auxiliary selection of litter size during pig breeding, can realize the early selection of parent pigs and even can accurately select parent pigs when the pigs are born. Generation interval is largely shortened, and selection progress is accelerated. The method has the advantages of simple operation, low condition requirements in polymerase chain reaction processes, short amplification fragment length (217bp), easy amplification, high amplification efficiency and accurate genotype judgement.

The invention relates to application of protein and proteome in preparation of a liver cirrhosis diagnostic reagent. The protein comprises Lumican, Tetranectin, Pro-platelet basic protein (PBP), Pigment epithelium-derived factor (PEDF), Insulin-like growth factor binding protein 3 (IGFbp-3), Sex hormone-binding globulin (SHBG), Thioredoxin and composition of parts in the liver cirrhosis diagnostic reagent. Multiple proteins related with health and disease states are identified and evaluated in large range by adopting a proteome technology, the screened biomarkers for identifying hepatitis and liver fibrosis are used for predicting the degree of hepatitis and liver fibrosis and can be used for preparing a kit for diagnosing liver cirrhosis and liver cirrhosis level, and the protein markers identify the sensitivity of liver cirrhosis and degree thereof; and by combining the optimal conditions of various protein markers, the sensitivity can reach 89 percent, the specificity reaches over 90 percent, and the sensitivity and the specificity are higher than those of any known detection method.

The invention relates to a Chinese medicinal composition for a kidney-yang deficiency and phlegm-retention type polycystic ovary syndrome. The Chinese medicinal composition comprises the following medicinal materials of epimedium, caladium, semen psoraleae, sliced deerhorn, sea horse, tortoise plastron and the like, does not contain rhubarb and Chinese angelica. The Chinese medicinal composition can reduce the level of androgens and androgen receptors of polycystic ovanian syndrome (PCOS) patients, improve the level of sex hormone binding globulin, reduce the level of free testosterone, improve the level of in-vivo estrogens, improve the growth and development of follicles and improve the ovulation rate and pregnancy rate of patients.

A method of birth control and hormone regulation comprises utilizing a vaginal ring worn continuously during each menstrual cycle. A vaginal ring delivers predetermined doses of progesterone and beta-estradiol. Beta-estradiol does not cause an increase in sex hormone binding globulin and thereby does not decrease a woman's levels of free testosterone and libido.

The inventors have proposed a novel panel of human plasma protein biomarkers for diagnosing hepatic fibrosis and cirrhosis. Presently there is no reliable non-invasive way of assessing liver fibrosis. A 2D-PAGE based proteomics study was used to identify potential fibrosis biomarkers. Plasma from patients with hepatic cirrhosis induced by infection with the hepatitis C virus (HCV) were analysed. Several proteins associated with liver scarring and potentially also related to viral infection were identified. These proteins include 14-3-3 protein zeta/delta, adiponectin, afamin, alpha-1-antitrypsin, alpha-2-HS-glycoprotein, apolipoprotein C-III, apolipoprotein E, C4b-binding protein beta chain, intact/cleaved complement C3dg, corticosteroid-binding globulin, fibrinogen gamma chain, beta haptoglobin at pH 5.46-5.49, haptoglobin-related protein, hemopexin, immunoglobulin J chain, leucine-rich alpha-2-glycoprotein, lipid transfer inhibitor protein, retinol-binding protein 4, serum paraoxonase/arylesterase 1, sex hormone-binding globulin and zinc-alpha-2-glycoprotein. These biomarkers can be used in conjunction with polypeptides in WO/2008/031051. The concentrations of these novel biomarkers can be determined using an immunoassay where the concentrations would reflect the extent of fibrosis. A fibrosis scoring scale for each of the novel biomarkers is proposed. The additive result from the scores of all the novel biomarkers would give a more reliable indication of the degree of fibrosis rather than examining individual biomarkers.

The invention relates to a serum protein marker group for diagnosis of type 1 and type 2 diabetes mellitus. The serum protein marker group is composed of the following serum protein markers: PZP, which has an Accession number of P20742, sex hormone binding globulin: SHBG, which has an Accession number of I3L145, C reactive protein: CRP, which has an Accession number of P02741, cholesteryl ester transfer protein: CETP, which has an Accession number of P11597, and a heparin cofactor 2: SERPIND1, which has an Accession number of P05546.

The invention discloses a sex hormone binding globulin preservation solution, a preparation method thereof and a detection agent and a kit for detecting the sex hormone binding globulin, and belongs to the technical field of in vitro diagnostic reagents. The sex hormone binding globulin preservation solution includes a buffer, a sex hormone, group IIA and/or IIB ions, a penetrating agent, an animal serum, a surfactant, and a protein stabilizer, wherein the concentration of the sex hormone in the preservation solution is 1-10 mu M, and the concentration of the Group IIA and/or IIB ions in the preservation solution is 10 to 60 mM. Both the detection agent and the kit contain the preservation solution. The sex hormone binding globulin preservation solution can stabilize the structure and biological activity of a sex hormone-binding globulin dimer dissolved in the preservation solution. The detection agent and the kit can ensure the detection accuracy of sex hormone binding globulin, and are convenient and quick.

There are provided methods for assaying biological specimens for steroids (androgens and estrogens), Sex Hormone-Binding Globulin (SHBG) and Albumin in order to calculate the free and bioavailable steroid concentration based on the laws of mass action and association constants predicated on the identification that one molar equivalent of SHBG contains two molar equivalents of steroid binding sites.

The invention discloses a kit for determining the content of sex hormone binding globulin (SHBG) in human serum by adopting magnetic particle chemiluminescence. The kit comprises a calibrator, a quality control material, a resistance agent, a magnetic particle agent and a luminescent substrate, wherein the resistance agent is prepared from fluorescein isothiocyanate labeled sex hormone-binding globulin coating antibody and an alkaline phosphatase labeled sex hormone-binding globulin labeling antibody; and the magnetic particle agent is a conjugate of magnetic particles and goat-anti FITC. By adopting the kit provided by the invention, a chemiluminescence technology and immunomagnetic particles are combined, a nearly homogenous reaction system is provided; in addition, a one-step reaction mode is adopted, the detection sensitivity and the precision are greatly improved, the detection range is enlarged, the reaction time is greatly shortened, is shorter than 25min from starting to add asample to obtaining a detection result and is obviously faster than the time of a similar kit; and in addition, multiple samples can be determined on a fully automatic chemiluminescence apparatus, sothat high-flux rapid determination of the sex hormone-binding globulin is realized, the accuracy is high, the specificity is strong, and the precision and the detection efficiency are greatly improved.

The invention belongs to the field of immunodetection, and particularly relates to a double-index immunochromatography kit for detecting adiponectin (Adipo) and sex hormone binding globulin (SHBG). The main component is an immunochromatography test strip, and the immunochromatography test strip is formed by sequentially pasting a sample pad, a binding pad, a nitrocellulose membrane and absorbent paper on a PVC base plate. Adipo antibody-microspheres and SHBG antibody-microspheres are adsorbed on the binding pad, an Adipo antibody is fixed on the nitrocellulose membrane to form a detection line 1 (T1 line), an SHBG antibody is fixed on the nitrocellulose membrane to form a detection line 2 (T2 line), and an anti-IgG antibody is fixed to form a quality control line (C line). The invention also discloses a process for coupling the Adipo antibody and the SHBG antibody with the microspheres. The Adipo/SHBG detection immunochromatography kit is used to determine the Adipo and SHBG concentrations in blood or other body fluids, and is used for early prediction of insulin resistance, type 2 diabetes mellitus and gestational diabetes mellitus occurrence risks.

A method for predicting the degree of weight loss in male subject attainable by applying one or more dietary interventions to a subject, said method comprising determining the level of one or more biomarkers in one or more samples obtained from the subject, wherein the biomarkers are selected from sex hormone-binding globulin, beta-2-microglobulin and serum paraoxonase/arylesterase.